Triple-Receptor Peptide Agonist Fully Reverses Memory Loss After Mild Traumatic Brain Injury in Mice
A GLP-1/GIP/glucagon triple receptor agonist fully reversed visual and spatial memory deficits in mice after mild traumatic brain injury, with protective effects lasting 30 days.
Quick Facts
What This Study Found
Triagonist (GLP-1/GIP/Gcg agonist) fully mitigated mTBI-induced visual and spatial memory deficits at 7 and 30 days post-injury via balanced activation of all three receptors.
Key Numbers
Triple agonist (GLP-1/GIP/Gcg); 7-day SC treatment; fully reversed visual/spatial memory deficits at d7 and d30; protected vs oxidative stress and glutamate toxicity
How They Did This
In vitro: SH-SY5Y neuronal cells treated with Triagonist; cAMP, oxidative stress, and glutamate toxicity assays; receptor antagonist blockade experiments. In vivo: mouse 30g weight-drop mTBI model; 7 days daily subcutaneous Triagonist; memory testing at 7 and 30 days post-injury.
Why This Research Matters
Mild TBI (concussion) affects millions yearly with no approved treatment. A peptide drug originally designed for metabolic disease that also protects the brain could be rapidly repurposed.
The Bigger Picture
Multi-receptor incretin agonists like tirzepatide are revolutionizing metabolic medicine. This study suggests their neuroprotective benefits may extend to traumatic brain injury — a field with zero approved drugs.
What This Study Doesn't Tell Us
Mouse model with unspecified group sizes; mild TBI only (not moderate/severe); mechanism of neuroprotection not fully elucidated in vivo; clinically translatable dose claim not validated in humans.
Questions This Raises
- ?Would the Triagonist work if administered days after injury instead of immediately?
- ?Is the neuroprotection primarily from GLP-1, GIP, or glucagon receptor activation?
- ?Could existing multi-agonists like tirzepatide provide similar TBI protection?
Trust & Context
- Key Stat:
- Full memory restoration Visual and spatial memory completely normalized at 7 and 30 days after mild TBI in treated mice
- Evidence Grade:
- Moderate — compelling animal results with in vitro mechanistic support, but unspecified group sizes and no human data.
- Study Age:
- Published in 2020; multi-receptor incretin agonists have since gained momentum with tirzepatide's success.
- Original Title:
- Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury.
- Published In:
- Experimental neurology, 324, 113113 (2020)
- Authors:
- Li, Yazhou(4), Glotfelty, Elliot J, Namdar, Inbar, Tweedie, David, Olson, Lars, Hoffer, Barry J, DiMarchi, Richard D, Pick, Chagi G, Greig, Nigel H
- Database ID:
- RPEP-04951
Evidence Hierarchy
Frequently Asked Questions
What is a triagonist?
A single peptide that activates three different receptors simultaneously — in this case GLP-1, GIP, and glucagon receptors — combining the benefits of all three.
Could this help people with concussions?
In mice, it completely reversed concussion-related memory problems. Human trials would be needed, but the drug class is already approved for diabetes, which could speed repurposing.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04951APA
Li, Yazhou; Glotfelty, Elliot J; Namdar, Inbar; Tweedie, David; Olson, Lars; Hoffer, Barry J; DiMarchi, Richard D; Pick, Chagi G; Greig, Nigel H. (2020). Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury.. Experimental neurology, 324, 113113. https://doi.org/10.1016/j.expneurol.2019.113113
MLA
Li, Yazhou, et al. "Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury.." Experimental neurology, 2020. https://doi.org/10.1016/j.expneurol.2019.113113
RethinkPeptides
RethinkPeptides Research Database. "Neurotrophic and neuroprotective effects of a monomeric GLP-..." RPEP-04951. Retrieved from https://rethinkpeptides.com/research/li-2020-neurotrophic-and-neuroprotective-effects
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.